Eosinophilic Granulomatosis with Polyangiitis (EGPA) is a rare autoimmune disease characterized by inflammation of blood vessels (vasculitis) and an increase in eosinophils, a type of white blood ...

Background: Eosinophilic granulomatosis with polyangiitis (EGPA) is an extremely rare type of vasculitis characterized by inflammation within small blood vessels or tissues that may cause damage to ...

Omalizumab is an anti-IgE monoclonal antibody used in severe allergic asthma. Herein, we describe a case of eosinophilic granulomatosis with polyangiitis, which manifested 3 months after initiation of ...

A STUDY has developed a predictive model for gastrointestinal (GI) lesions in patients with eosinophilic granulomatosis with polyangiitis (EGPA), shedding light on this serious complication and its ...

Background: Eosinophilic granulomatosis with polyangiitis (EGPA) is a systemic autoimmune disease characterised by eosinophilia and small-vessel inflammation. Thromboembolism is a relatively common ...

Others, such as eosinophilic granulomatosis with polyangiitis, tend to develop in adults. Symptoms of autoimmune vasculitis can vary depending on the type of condition and which parts of your body ...

GlaxoSmithKline’s Nucala (mepolizumab) has gained a new FDA approval for the rare autoimmune disease eosinophilic granulomatosis with polyangiitis (EGPA). Nucala, an interleukin-5 (IL-5 ...

The leading Severe Asthma Companies such as Kinaset Therapeutics, Bio-Thera Solutions, CSPC ZhongQi Pharmaceutical Technology ...

GSK plc GSK recently announced that EMA has accepted the regulatory filing seeking approval for its IL-5 inhibitor ...

Depemokimab is a follow-up to GSK's Nucala (mepolizumab), a once-monthly IL-5 inhibitor approved for severe asthma, CRSwNP, ...

Well, we are very excited that we have multiple development in the study of treatment of vasculitis, and this is all because ...

GSK plc (LSE/NYSE: GSK) today announced that the European Medicines Agency has accepted for review the Marketing Authorisation Application for the use of depemokimab in two indications. The submitted ...